You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent mantle cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Low Dose Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Duarte, California
  • +1 more
Aug 3, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)

Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biopsy
  • +10 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 9, 2023

Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +9 more
  • Cryosurgery
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 9, 2022

Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

Not yet recruiting
  • Post-Transplant Lymphoproliferative Disorder
  • +10 more
  • Loncastuximab Tesirine
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2022

Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United

Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
May 10, 2022

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Acalabrutinib
    • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    • Duarte, California
      City of Hope Comprehensive Cancer Center
    Jun 16, 2022

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

    Completed
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +8 more
    • PI3K inhibitor BKM120
    • +3 more
    • Atlanta, Georgia
    • +1 more
    Jun 27, 2022

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous

    Not yet recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Anti-CD19-CAR CMV-specific T-lymphocytes
    • +3 more
    • Duarte, California
      City of Hope Medical Center
    Jun 28, 2022

    Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)

    Active, not recruiting
    • Mantle Cell Lymphoma Recurrent
    • ibrutinib and Tisagenlecleucel
    • Melbourne, Victoria, Australia
      Peter Mac Callum Cancer Centre
    Nov 4, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +23 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 23, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

    Completed
    Has Results
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Dec 10, 2021

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +20 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 11, 2022

    Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in

    Completed
    Has Results
    • Contiguous Stage II Mantle Cell Lymphoma
    • +5 more
    • Duarte, California
    • +1 more
    Jan 12, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +13 more
    • Polatuzumab Vedotin
    • +3 more
    • Scottsdale, Arizona
    • +11 more
    Aug 23, 2022